Valneva: quarterly results boosted by PRV sale

(CercleFinance.com) - Valneva reports Q1 2024 net income of E58.
9m, reflecting the sale of the Priority Review Voucher (PRV), versus a loss of E18.1m a year earlier, with adjusted EBITDA up from -E12.3m to +E73m.

The vaccines company's total sales fell 2% to E32.8m, with product sales stable at E32.1m, including E16.6m for Ixiaro/Jespect (Japanese encephalitis) and E11.3m for Dukoral (cholera).

Valneva confirms that it expects total sales for the current year between E170m and E190m, including E160m to E180m thanks to growth in sales of its proprietary vaccines.

For the remainder of the year, it expects to continue to benefit from the recovery in the travel industry, and at the same time achieve the various R&D milestones we have set ourselves.


Copyright (c) 2024 CercleFinance.com. All rights reserved.